These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 39073797)

  • 21. Increases in statin eligibility to reduce cardiovascular risk according to the 2013 ACC/AHA cholesterol guidelines in the Africa Middle East region: a sub-analysis of the Africa Middle East Cardiovascular Epidemiological (ACE) study.
    Hamoui O; Omar MI; Raal FJ; Rashed W; Kane A; Alami M; Abreu P; Mashhoud W; Alsheikh-Ali AA
    BMC Cardiovasc Disord; 2019 Mar; 19(1):61. PubMed ID: 30876390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guideline-Based Statin Eligibility, Coronary Artery Calcification, and Cardiovascular Events.
    Pursnani A; Massaro JM; D'Agostino RB; O'Donnell CJ; Hoffmann U
    JAMA; 2015 Jul; 314(2):134-41. PubMed ID: 26172893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers.
    Akhabue E; Rittner SS; Carroll JE; Crawford PM; Dant L; Laws R; Leo MC; Puro J; Persell SD
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28673901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of ACC/AHA and ESC Guideline Recommendations Following Trial Evidence for Statin Use in Primary Prevention of Cardiovascular Disease: Results From the Population-Based Rotterdam Study.
    Pavlovic J; Greenland P; Deckers JW; Brugts JJ; Kavousi M; Dhana K; Ikram MA; Hofman A; Stricker BH; Franco OH; Leening MJ
    JAMA Cardiol; 2016 Sep; 1(6):708-13. PubMed ID: 27439175
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel method versus the Friedewald method for estimating low-density lipoprotein cholesterol in determination of the eligibility for statin treatment for primary prevention in the United States.
    Shin D; Bohra C; Kongpakpaisarn K
    Medicine (Baltimore); 2018 Apr; 97(17):e0612. PubMed ID: 29703063
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-life evaluation of European and American high-risk strategies for primary prevention of cardiovascular disease in patients with first myocardial infarction.
    Mortensen MB; Falk E
    BMJ Open; 2014 Oct; 4(10):e005991. PubMed ID: 25326211
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the European and US guidelines for lipid-lowering therapy in primary prevention of cardiovascular disease.
    Delabays B; de La Harpe R; Vollenweider P; Fournier S; Müller O; Strambo D; Graham I; Visseren FLJ; Nanchen D; Marques-Vidal P; Vaucher J
    Eur J Prev Cardiol; 2023 Nov; 30(17):1856-1864. PubMed ID: 37290056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
    Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
    JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential Cardiovascular Disease Events Prevented with Adoption of the 2017 American College of Cardiology/American Heart Association Blood Pressure Guideline.
    Bress AP; Colantonio LD; Cooper RS; Kramer H; Booth JN; Odden MC; Bibbins-Domingo K; Shimbo D; Whelton PK; Levitan EB; Howard G; Bellows BK; Kleindorfer D; Safford MM; Muntner P; Moran AE
    Circulation; 2019 Jan; 139(1):24-36. PubMed ID: 30586736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Further insight into the cardiovascular risk calculator: the roles of statins, revascularizations, and underascertainment in the Women's Health Study.
    Cook NR; Ridker PM
    JAMA Intern Med; 2014 Dec; 174(12):1964-71. PubMed ID: 25285455
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Risk and Statin Eligibility in Primary Prevention: A Comparison between the Brazilian and the AHA/ACC Guidelines.
    Cesena FHY; Valente VA; Santos RD; Bittencourt MS
    Arq Bras Cardiol; 2020 Sep; 115(3):440-449. PubMed ID: 33027365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Implications of the new American College of Cardiology/American Heart Association cholesterol guidelines for primary atherosclerotic cardiovascular disease event prevention in a multi ethnic cohort: Multi-Ethnic Study of Atherosclerosis (MESA).
    Yeboah J; Sillau S; Delaney JC; Blaha MJ; Michos ED; Young R; Qureshi WT; McClelland R; Burke GL; Psaty BM; Herrington DM
    Am Heart J; 2015 Mar; 169(3):387-395.e3. PubMed ID: 25728729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
    Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide.
    Pokharel Y; Tang F; Jones PG; Nambi V; Bittner VA; Hira RS; Nasir K; Chan PS; Maddox TM; Oetgen WJ; Heidenreich PA; Borden WB; Spertus JA; Petersen LA; Ballantyne CM; Virani SS
    JAMA Cardiol; 2017 Apr; 2(4):361-369. PubMed ID: 28249067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of the 2016 USPSTF recommendations for primary cardiovascular prevention in a large contemporary cohort.
    Schonmann Y; Bleich O; Matalon A; Yeshua H
    Eur J Prev Cardiol; 2018 May; 25(8):870-880. PubMed ID: 29517367
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparing Guidelines for Statin Treatment in Canada and the United States.
    Hennessy DA; Bushnik T; Manuel DG; Anderson TJ
    J Am Heart Assoc; 2015 Jul; 4(7):. PubMed ID: 26175357
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Applicability and potential clinical effects of 2013 cholesterol guidelines on major cardiovascular events.
    Ko MJ; Kim YJ; Park CM; Lee SM; Lee WJ; Pencina MJ; Navar-Boggan AM; Park DW
    Am Heart J; 2015 Sep; 170(3):598-605.e7. PubMed ID: 26385045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trends in Provision of Medications and Lifestyle Counseling in Ambulatory Settings by Gender and Race for Patients With Atherosclerotic Cardiovascular Disease, 2006-2016.
    Mufarreh A; Shah AJ; Vaccarino V; Kulshreshtha A
    JAMA Netw Open; 2023 Jan; 6(1):e2251156. PubMed ID: 36656581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessing potential population impact of statin treatment for primary prevention of atherosclerotic cardiovascular diseases in the USA: population-based modelling study.
    Yang Q; Zhong Y; Gillespie C; Merritt R; Bowman B; George MG; Flanders WD
    BMJ Open; 2017 Jan; 7(1):e011684. PubMed ID: 28119384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The new pooled cohort equations risk calculator.
    Preiss D; Kristensen SL
    Can J Cardiol; 2015 May; 31(5):613-9. PubMed ID: 25843167
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.